Hao Yu

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 591 citations · Full text

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Yongkun Sun, Wei Niu, Feng Du et al. · Journal of Hematology & Oncology · 2016 · 421 citations · Full text

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Yihebali Chi, Zhiwei Fang, Xiaonan Hong et al. · Clinical Cancer Research · 2018 · 322 citations

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer

Xichun Hu, Jun Cao, Wenwei Hu et al. · BMC Cancer · 2014 · 233 citations · Full text

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

Ying Cheng, Qiming Wang, Kai Li et al. · British Journal of Cancer · 2021 · 141 citations · Full text

Placebo-controlled Phase 2, Further-line Treatment, Medicine +9